(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.25%) $83.78
(-3.36%) $1.583
(0.04%) $2 343.50
(0.26%) $27.43
(0.70%) $926.90
(0.03%) $0.932
(0.10%) $10.96
(0.00%) $0.799
(0.00%) $92.17
-1.27% ¥ 3 115.00
Live Chart Being Loaded With Signals
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products...
Stats | |
---|---|
Today's Volume | 25 000.00 |
Average Volume | 35 132.00 |
Market Cap | 107.45B |
EPS | ¥0 ( 2024-02-04 ) |
Next earnings date | ( ¥0 ) 2024-05-12 |
Last Dividend | ¥40.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 36.30 |
ATR14 | ¥4.77 (0.15%) |
Volume Correlation
Mochida Pharmaceutical Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Mochida Pharmaceutical Correlation - Currency/Commodity
Mochida Pharmaceutical Financials
Annual | 2022 |
Revenue: | ¥103.26B |
Gross Profit: | ¥55.12B (53.37 %) |
EPS: | ¥178.93 |
Q3 | 2023 |
Revenue: | ¥28.74B |
Gross Profit: | ¥14.83B (51.59 %) |
EPS: | ¥45.16 |
Q2 | 2023 |
Revenue: | ¥24.73B |
Gross Profit: | ¥12.31B (49.78 %) |
EPS: | ¥32.28 |
Q1 | 2023 |
Revenue: | ¥24.75B |
Gross Profit: | ¥13.21B (53.36 %) |
EPS: | ¥46.23 |
Financial Reports:
No articles found.
Mochida Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥40.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥9.38 | 2001-03-27 |
Last Dividend | ¥40.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥1 333.13 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.96 | -- |
Div. Sustainability Score | 7.75 | |
Div.Growth Potential Score | 2.28 | |
Div. Directional Score | 5.01 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8354.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7733.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6914.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6273.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4985.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
4200.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3397.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2487.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
9414.T | Ex Dividend Junior | 2023-08-30 | Annually | 0 | 0.00% | |
8078.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0301 | 1.500 | 9.40 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0191 | 1.200 | 9.36 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0237 | 1.500 | -0.848 | -1.272 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.39 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.04 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.157 | 1.500 | 4.68 | 7.02 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 3 942.00 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 32.98 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 8.79 | 2.00 | 5.61 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.512 | 1.000 | 4.79 | 4.79 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0394 | 1.000 | -1.212 | -1.212 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.634 | 0.800 | 9.11 | 7.28 | [0.5 - 2] |
Total Score | 7.75 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 37.01 | 1.000 | 6.36 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0237 | 2.50 | -0.545 | -1.272 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 8.79 | 2.00 | 7.07 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.55 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 32.98 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.043 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0117 | 1.000 | -2.21 | 0 | [0.1 - 0.5] |
Total Score | 2.28 |
Mochida Pharmaceutical
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators